title: Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.
abstract: In a rabbit model of Streptococcus pneumoniae meningitis single doses of 10 and 2.5 mg of the glycopeptide LY333328 per kg of body weight reduced bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as ceftriaxone at 10 mg/kg/h (changes in log CFU, -0.29 +/- 0.21 and -0.26 +/- 0.22 versus -0.34 +/- 0.15/ml/h). A dose of 1 mg/kg was bacteriostatic (change in log CFU, 0.01 +/- 0.11/ml/h). In two animals receiving LY333328 at a dose of 40 mg/kg the bacterial titers were reduced by 0.54 and 0.51 log CFU/ml/h. The penetration of CSF by LY333328 was 1 to 5%. The concentrations of lipoteichoic and teichoic acids in CSF and neuronal damage were similar in ceftriaxone- and LY333328-treated animals.
authors.affiliation: Department of Neurology, University of Göttingen, Göttingen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Gerber
authors.forename: A
authors.initials: A
authors.lastname: Smirnov
authors.forename: A
authors.initials: A
authors.lastname: Wellmer
authors.forename: J
authors.initials: J
authors.lastname: Ragheb
authors.forename: J
authors.initials: J
authors.lastname: Prange
authors.forename: E
authors.initials: E
authors.lastname: Schütz
authors.forename: K
authors.initials: K
authors.lastname: Wettich
authors.forename: S
authors.initials: S
authors.lastname: Kalich
authors.forename: R
authors.initials: R
authors.lastname: Nau
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017209:Apoptosis; D019540:Area Under Curve; D002555:Cerebrospinal Fluid / Q000187:drug effects / Q000382:microbiology; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D008586:Meningitis, Pneumococcal / Q000188:drug therapy* / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010406:Penicillins / Q000494:pharmacology; D011817:Rabbits; D013296:Streptococcus pneumoniae / Q000187:drug effects; D016896:Treatment Outcome; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010406:Penicillins; C100708:oritavancin; D014640:Vancomycin